Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

BACKGROUND Combination antiretroviral therapy suppresses but does not eradicate human immunodeficiency virus type 1 (HIV-1) in infected persons, and low-level viremia can be detected despite years of suppressive antiretroviral therapy. Short-course (28-day) intensification of standard antiretroviral combination therapy is a useful approach to determine whether complete rounds of HIV-1 replication in rapidly cycling cells contribute to persistent viremia. We investigated whether intensification with the integrase inhibitor raltegravir decreases plasma HIV-1 RNA levels in patients receiving suppressive antiretroviral therapy. METHODS Subjects (n = 10) with long-term HIV-1 suppression receiving combination antiretroviral regimens had their regimens intensified for 4 weeks with raltegravir. Plasma HIV-1 RNA level was determined before, during, and after the 4-week intensification period, using a sensitive assay (limit of detection, 0.2 copies of HIV-1 RNA/mL of plasma). A 4-week intensification course was chosen to investigate potential HIV-1 replication in cells with relatively short (approximately 1-14-day) half-lives. RESULTS There was no evidence in any subject of a decline in HIV-1 RNA level during the period of raltegravir intensification or of rebound after discontinuation. Median levels of HIV-1 RNA before (0.17 log10 copies/mL), during (0.04 log10 copies/mL), and after (0.04 log10 copies/mL) raltegravir intensification were not significantly different (P > .1 for all comparisons in parametric analyses). High-performance liquid chromatography and mass spectroscopy experiments confirmed that therapeutic levels of raltegravir were achieved in plasma during intensification. CONCLUSIONS Intensification of antiretroviral therapy with a potent HIV-1 integrase inhibitor did not decrease persistent viremia in subjects receiving suppressive regimens, indicating that rapidly cycling cells infected with HIV-1 were not present. Eradication of HIV-1 from infected persons will require new therapeutic approaches. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT00618371.

[1]  Hélène Jacqmin-Gadda,et al.  Mixed models for longitudinal left-censored repeated measures , 2004, Comput. Methods Programs Biomed..

[2]  I. Grant,et al.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. , 2008, Archives of neurology.

[3]  I. Pastan,et al.  Anti‐HIV‐1 immunotoxin 3B3(Fv)‐PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques , 2006, Journal of leukocyte biology.

[4]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Shaik,et al.  P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution , 2007, Drug Metabolism and Disposition.

[6]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[7]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[8]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[9]  L. Varatharajan,et al.  The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research , 2009, Antiviral research.

[10]  J. Wagner,et al.  Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.

[11]  C. Crumpacker,et al.  Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.

[12]  M. Peeters,et al.  Comparison of human immunodeficiency virus biological phenotypes isolated from cerebrospinal fluid and peripheral blood , 1995, Journal of medical virology.

[13]  Yang Wang,et al.  Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus , 2005, Journal of Virology.

[14]  J. Hughes,et al.  Mixed Effects Models with Censored Data with Application to HIV RNA Levels , 1999, Biometrics.

[15]  W. Haefeli,et al.  Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. , 2007, Biochemical pharmacology.

[16]  J. Mellors,et al.  Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. , 2009, The Journal of infectious diseases.

[17]  D. Ho,et al.  Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.

[18]  I. Grant,et al.  Low atazanavir concentrations in cerebrospinal fluid , 2009, AIDS.

[19]  D. Hazuda,et al.  Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase , 2007, AIDS.

[20]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[21]  J. Clements,et al.  The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: A model for human immunodeficiency virus patients on highly active antiretroviral therapy , 2005, Journal of NeuroVirology.

[22]  Mario Clerici,et al.  Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years , 2003, Journal of Virology.

[23]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[24]  E. Acosta,et al.  A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  T. Greenough,et al.  Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy , 2009, Journal of Virology.

[26]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[27]  A. Sher,et al.  A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression. , 2001, The Journal of infectious diseases.

[28]  Alan S. Perelson,et al.  In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months , 2003, Journal of Virology.

[29]  Lawrence Corey,et al.  Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. , 2007, The Journal of infectious diseases.

[30]  L. Varatharajan,et al.  Corrigendum to “The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research” [Antiviral Res. 82 (2) (2009) A99–A109] , 2009, Antiviral Research.

[31]  R. Haubrich,et al.  Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. , 2008, The Journal of infectious diseases.

[32]  S J Gange,et al.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.

[33]  D. Hazuda,et al.  Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[34]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[35]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[36]  Alan S Perelson,et al.  Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication , 2004, Journal of acquired immune deficiency syndromes.

[37]  Joseph A Kovacs,et al.  ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.

[38]  R. Siliciano,et al.  HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. , 2001, JAMA.

[39]  C. Kovacs,et al.  Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.

[40]  A. Trkola,et al.  HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.

[41]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[42]  T. Chun,et al.  Latent reservoirs of HIV: obstacles to the eradication of virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.